Navigation Links
Lorus initiates development program exploring novel route of administration for LOR-2040
Date:4/22/2008

TORONTO, April 22 /PRNewswire-FirstCall/ - Lorus Therapeutics Inc. ('Lorus'), a biopharmaceutical company specializing in the research and development of pharmaceutical products and technologies for the management of cancer, today announced the start of a development program aimed at expanding the therapeutic application of its lead clinical-stage drug LOR-2040 for the treatment of superficial bladder cancer.

The new development program will examine direct (intravesical) administration of LOR-2040 into the bladder as a treatment for superficial or non-invasive bladder cancer. Formal toxicology evaluation, which is currently in progress, will be used to determine the appropriate human dose and dose schedule for LOR-2040 with this route of administration.

Results of these studies will be used in support of an Investigational New Drug (IND) application for the use of LOR-2040 in the treatment of bladder cancer. Lorus intends to submit the IND during Q3, 2008, following successful completion of the toxicology program.

LOR-2040, formerly known as GTI-2040, has shown potent antiproliferative activity and target downregulation in bladder cancer in preclinical studies. LOR-2040 is currently being investigated in several phase I and phase II clinical trials in a broad range of cancer indications, both alone and in combination with a number of standard cancer therapies. In clinical trials, LOR-2040 has demonstrated a high safety profile when administered intravenously, which is the current route of administration for this drug.

In the U.S. more than 60,000 new cases of bladder cancer are diagnosed each year, which accounts for approximately 13,000 deaths annually. At initial diagnosis, up to 90% of subjects with bladder cancers have superficial disease that is confined to the inner layers of tissue in the urinary bladder. Systemic chemotherapy is considered less effective than the intravesical (instilled in the bladder) agents in treating lo
'/>"/>

SOURCE Lorus Therapeutics Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. Lorus Therapeutics presents new findings for the anticancer drugs LOR-253 and LOR-2040
2. Lorus Therapeutics Announces Exclusive Multinational License Agreement with Zoticon Bioventures for Virulizin(R)
3. Lorus Therapeutics Appoints Peter Korth as Chief Financial Officer
4. Lorus Advances Clinical Development of GTI-2040 Combined with Ara-C in Acute Myeloid Leukemia
5. SemBioSys initiates toxicology study for safflower-produced insulin
6. Nereus Pharmaceuticals Initiates Clinical Trial of NPI-2358 in Non-Small Cell Lung Cancer Following Encouraging Phase 1 Data
7. Aegera initiates Phase 1 clinical trial of AEG33773 - A small molecule in development for diabetic neuropathic pain
8. TorreyPines Therapeutics Initiates Phase II Study of Muscarinic Agonist NGX267 for Treatment of Xerostomia
9. NicOx Initiates Two Large ABPM Studies for Naproxcinod in Hypertensive Patients with Osteoarthritis
10. Circassia Initiates Phase II Clinical Study With Novel Anti-Allergy Technology
11. Alexza Initiates First Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2009)... Vivakor, Inc. (OTC Bulle...ders of record on December 1, 2009 will receive th...ica, Inc. that was previously approved by Vivakor,...Nevada corporation of which Vivakor owned approxim...record date. The distribution date is still expect...
(Date:12/3/2009)...swire/ -- JourneyLite of Houston, LLC announced ...tients a second surgical option, vertical sleeve ...m that it currently performs. The first sleeve ga...by surgeon partner, Matthew St. Laurent, MD on O...well. ,, The Vertical Sleeve Gastrectomy (also ...
(Date:12/3/2009)...wswire-FirstCall/ -- Shire plc (LSE: SHP, Nasdaq: ...ompany, today announced a voluntary recall of five...f the Attention-Deficit/Hyperactivity Disorder (AD...ction because some Daytrana patches do not meet or...moval specification, and as a result, patients and...
(Date:12/3/2009)...a, Dec. 3 /PRNewswire-Asia/ -- Dr. Susan Jiang, M.... Biotechnology Co. Ltd.,( http://www.beikebiotech....c,Foot Care in New Delhi, India, November 22, 2009...regenerative medicine company. , The conf...on (IPA), aimed,to help podiatrists and researcher...
Breaking Biology Technology:Vivakor Confirms Record Date of Stock Dividend 2Vivakor Confirms Record Date of Stock Dividend 3JourneyLite of Houston Now Offering Sleeve Gastrectomy 2Non-safety-related voluntary recall of a limited portion of Daytrana(R) (methylphenidate transdermal system) patches announced 2Non-safety-related voluntary recall of a limited portion of Daytrana(R) (methylphenidate transdermal system) patches announced 3Non-safety-related voluntary recall of a limited portion of Daytrana(R) (methylphenidate transdermal system) patches announced 4Non-safety-related voluntary recall of a limited portion of Daytrana(R) (methylphenidate transdermal system) patches announced 5Beike Biotechnology CSO Speaks on Role of Stem Cells in Treating Diabetic Foot Disease at IPA Diabetic Foot Care Conference, India 2Beike Biotechnology CSO Speaks on Role of Stem Cells in Treating Diabetic Foot Disease at IPA Diabetic Foot Care Conference, India 3
..., Wis. - Space Place , the University of Wiscons...ving to a new location at Villager Mall, opening S...hrough Thursday, Sept. 1 and are free and open to ...ther place where we,d been for 15 years," said dir... has increased steadily every year, and our ambiti...
..., Wis. - The life sciences company Promega announ...with Australian firm Benitec that had been pending...der the terms of the settlement, Promega will hold... make and sell research products based around Beni...ology. Promega will also receive a combined paymen...
...of business investors and government representativ... Act 255 that was enacted to stimulate investments...ere made to a state Senate committee on Wednesday....ill stymie business investment in high-growth comp...ecommendations: , , Increasing from $30 million to...
Other Biology Technology:Space Place opens new astronomy center 2Suggestions offered to foster high-growth business investment 2
(Date:12/4/2009)...skovar, a Texas AgriLife Research plant physiologi...nter in Uvalde, has been investigating ways to hel...n from the greenhouse to the field. , "This rese...ibly even the further profitability of some vegeta... plants that will establish well," Leskovar said. ...
(Date:12/4/2009)...lable in German . , A new study of the Max Pl... understand the positive effect of dietary restric...ferent organisms (fruit flies and mice) have shown... with a potential negative side effect of diminish...ess frequently with a reduced litter size on a low...
(Date:12/3/2009)...n new information and adapt to changes in our dail...ies, appears to lie in the minute junctions where ...by NYU Langone Medicine Center researchers. The st...Nature . , The scientists, led by Wen-Biao Gan,...cience at NYU School of Medicine, discovered that ...
Breaking Biology News(10 mins):Texas AgriLife researchers helping 2Texas AgriLife researchers helping 3Texas AgriLife researchers helping 4How nutrition affects healthy aging 2Lifelong memories linked to stable nerve connections 2Profiles International Finds High Employee Utilization is One Key to Maximizing Productivity 58447 1Profiles International Finds High Employee Utilization is One Key to Maximizing Productivity 58447 2Profiles International Finds High Employee Utilization is One Key to Maximizing Productivity 58447 3New Online Continuing Education Course on Near Death Experience Added to HealthForumOnline 26apos 3Bs Library for Mental Health Professionals 58442 1New Online Continuing Education Course on Near Death Experience Added to HealthForumOnline 26apos 3Bs Library for Mental Health Professionals 58442 2New Online Continuing Education Course on Near Death Experience Added to HealthForumOnline 26apos 3Bs Library for Mental Health Professionals 58442 3New Online Continuing Education Course on Near Death Experience Added to HealthForumOnline 26apos 3Bs Library for Mental Health Professionals 58442 4New Online Continuing Education Course on Near Death Experience Added to HealthForumOnline 26apos 3Bs Library for Mental Health Professionals 58442 5Paul Marks prize recognizes 3 young cancer researchers 58437 1Paul Marks prize recognizes 3 young cancer researchers 58437 2Paul Marks prize recognizes 3 young cancer researchers 58437 3Paul Marks prize recognizes 3 young cancer researchers 58437 4Paul Marks prize recognizes 3 young cancer researchers 58437 5
...serious suicide attempts or death by suicide gener...aking antidepressant medication, according to a ne...s and published in the January issue of The Americ...t the risk of suicidal behavior after starting 10 ...risk posed by older medications. , These findings...
...l rate of incidence and mortality-the number of th...om it-Glioblastoma Multiforme (GBM) is a brain can...people who are diagnosed with GBM annually in the ...thin 3 years. Currently, the only treatments that ... surgeries to remove the tumor and radiation treat...
...have developed a method to engineer blood vessels ...uscle. Trials have resulted in significant improv...n the journal Artificial Organs. , With heart di...uting to increasing mortality rates, there has bee... the specific challenges in the field of tissue en...
Other Biology News:Suicide risk does not increase when adults start using antidepressants, study finds 2Radiotherapy advance points way to noninvasive brain cancer treatment 2Radiotherapy advance points way to noninvasive brain cancer treatment 3
Mouse IgM EIA Kit from Assay Designs/Stressgen Bioreagents
Custom Human Cytokine Antibody Array, Choose from hundreds of proteins. from Raybiotech, Inc.
Goat Anti-Mouse Ig + IgM Antibody, FITC Conjugated from Cayman Chemical
CopyControl Induction Solution from EPICENTRE Biotechnologies
Biology Products: